Bingham Osborn & Scarborough’s Edwards Lifesciences EW Stock Holding History

Bingham Osborn & Scarborough’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,686	Closed	-$324K	–	165
2020 Q2	$324K	Sell	4,686 -9	-0.2%	-$640	0.03%	114
2020 Q1	$295K	Buy	4,695 +24	+0.5%	+$1.73K	0.03%	111
2019 Q4	$363K	Sell	4,671 -12	-0.3%	-$937	0.03%	112
2019 Q3	$343K	Buy	4,683 +36	+0.8%	+$2.53K	0.03%	109
2019 Q2	$286K	Buy	4,647 +24	+0.5%	+$1.45K	0.03%	114
2019 Q1	$295K	Hold	4,623	–	–	0.03%	117
2018 Q4	$236K	Hold	4,623	–	–	0.02%	121
2018 Q3	$268K	Hold	4,623	–	–	0.02%	119
2018 Q2	$224K	Buy	4,623 +186	+4%	+$8.68K	0.02%	129
2018 Q1	$206K	Buy	+4,437	New	+$193K	0.02%	138

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bingham Osborn & Scarborough's EW Position: Q3 2020 in Review

Bingham Osborn & Scarborough sold out of Edwards Lifesciences (EW) in Q3 2020, closing a stake of 4,686 shares — an estimated $324K sold.

Bingham Osborn & Scarborough first reported a position in EW in Q1 2018 and held it in 10 quarters. The position peaked at $363K in Q4 2019. 1,083 funds tracked by Wall St. Rank hold EW as of Q3 2020.

Bingham Osborn & Scarborough reported no remaining Edwards Lifesciences position as of Q3 2020 after selling out during the quarter.
Bingham Osborn & Scarborough sold 4,686 Edwards Lifesciences shares in Q3 2020, an estimated $324K.
Bingham Osborn & Scarborough first reported a position in Edwards Lifesciences in Q1 2018 and held it in 10 quarters.
Bingham Osborn & Scarborough's Edwards Lifesciences position peaked at $363K in Q4 2019.
1,083 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q3 2020, filed 4 Nov 2020.